Search
fenoldopam (Corlopam)
Tradename: Corlopam (fenoldopam mesylate)
Indications:
1) emergency treatment of severe hypertension
2) may benefit a subgroup of patients with acute tubular necrosis (ATN) [3]
3) risk reduction for acute renal failure in critically ill patients [4]
4) no benefit for acute kidney injury* after cardiac surgery [5]
* serum creatinine increase > 50% above baseline
Contraindications:
-> does NOT prevent contrast nephropathy
Adverse effects:
- hypotension [5]
Mechanism of action:
1) dopamine D1 receptor agonist
2) may inhibit catecholamine uptake
3) increases blood flow to renal cortex & outer medulla
Interactions
drug interactions
drug adverse effects (more general classes)
General
adrenergic neuron inhibitor
dopaminergic receptor agonist
Properties
AGONIST-FOR: adrenergic receptor
Database Correlations
PUBCHEM correlations
References
- Journal Watch 23(24):193, 2003
Stone GW et al
Fenoldopam mesylate for the prevention of contrast-induced
nephropathy: a randomized controlled trial.
JAMA 290:2284, 2003
PMID: 14600187
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996 pg 211-212
- Journal Watch 25(17):135, 2005
Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD.
Fenoldopam mesylate in early acute tubular necrosis: a
randomized, double-blind, placebo-controlled clinical trial.
Am J Kidney Dis. 2005 Jul;46(1):26-34.
PMID: 15983954
- Landoni G et al,
Beneficial impact of fenoldopam in critically ill patients
with or at risk for acute renal failure: A meta-analysis of
randomized clinical trials.
Am J Kidney Dis 2007, 49:56
PMID: 17185146
- Bove T et al.
Effect of fenoldopam on use of renal replacement therapy among
patients with acute kidney injury after cardiac surgery:
A randomized clinical trial.
JAMA 2014 Sep 29;
PMID: 25265449